A new oral medication, daraxonrasib, produced striking results in a phase 3 trial for people with pancreatic cancer, offering hope against one of the deadliest cancers.
Key trial findings
– The RASolute 302 phase 3 study enrolled 500 participants with solid tumors driven by activating RAS mutations (a mutation present in roughly 92% of pancreatic cancers). The analysis reported here focused on 168 patients who had previously received chemotherapy.
– Daraxonrasib was tested at doses from 10 mg to 400 mg once daily; 300 mg was chosen for the phase 3 regimen.
– Patients treated with daraxonrasib had a median survival of about 13 months from diagnosis compared with about 6 months for those receiving standard chemotherapy — a roughly 60% reduction in the risk of death in the daraxonrasib group.
– For patients with a common RAS mutation called G12, disease control lasted a median of about 7 months on daraxonrasib versus about 3 months with chemotherapy.
– Objective response rates (the share of patients whose tumors shrank or disappeared) were substantially higher with daraxonrasib: roughly 31% overall versus 11% with chemotherapy, and about 33% versus 12% among those with the G12 mutation.
What daraxonrasib is and how it works
Daraxonrasib is the first in a new class of agents called RAS(ON) inhibitors. These drugs are designed to target specific, cancer-driving variants of the RAS gene that help tumors grow. By blocking those mutant RAS proteins, the drug aims to slow tumor growth and, as the trial results indicate, can shrink tumors in a meaningful fraction of patients.
Safety and side effects
– Most participants reported side effects: about 96% of those who received doses of 300 mg or less experienced at least one adverse event.
– Severe side effects (grade 3 or higher) occurred in roughly one-third of patients.
– Some experts note the adverse-event profile appeared more favorable than that of the typical second-line chemotherapy regimens used in this setting, but access and cost will be important considerations if the drug receives approval.
Expert reactions and next steps
Investigators and outside experts described the results as highly encouraging. Academic leaders said the findings represent a potentially transformative advance for pancreatic cancer care, especially given how limited effective options have been for patients whose disease progresses after first-line chemotherapy. The trial results were published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO) annual meeting.
Manufacturers and researchers will need to pursue regulatory review and confirmatory work, and health systems will face decisions about coverage and access if the drug is approved.
Why this matters for pancreatic cancer
Pancreatic cancer has a very high mortality rate, in part because it is usually diagnosed late. Current national estimates indicate tens of thousands of new U.S. cases each year and a large proportion of deaths: most patients are diagnosed at an advanced stage, and five-year survival for metastatic disease remains low.
Several factors make the disease hard to treat: the pancreas sits deep in the abdomen (making early detection difficult), tumors often have dense connective tissue that impedes drug delivery, and pancreatic cancers frequently harbor aggressive genetic changes such as RAS mutations.
Current treatments and prevention
Treatment options include surgery (for localized disease), radiation, systemic chemotherapy, targeted therapies, and immunotherapy. Early detection offers the best chance to change outcomes, but there is no routine screening for the general population. People at high risk — for example those with strong family histories or known hereditary cancer syndromes such as BRCA mutations or Lynch syndrome — should discuss screening with their doctors, which may include MRI or endoscopic ultrasound.
Lifestyle changes can lower some risk factors: avoiding tobacco, maintaining a healthy weight, exercising regularly, and limiting alcohol may reduce the chance of developing pancreatic cancer.
Bottom line
Daraxonrasib, an oral RAS(ON) inhibitor, produced substantial improvements in survival and tumor response in a phase 3 trial for patients with RAS-driven pancreatic cancer who had previously received chemotherapy. Side effects were common and sometimes severe, but experts regard the results as a major step forward for a disease that has had few effective second-line options. Further regulatory review and broader access decisions will determine how quickly patients can benefit from this new treatment.